Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$58.52−0.88 (-1.48%)
Close on Nov 18, 2026Market cap $8.71BP/E –Yield 0.00%
Vaxcyte shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Vaxcyte's shares outstanding was 144M at Jun 30, 2026. For fiscal 2025 it was 136M, up 11.6% from the year before. The highest annual figure on record is 136M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 136M | +11.6% |
| FY2024 | Dec 31, 2024 | 122M | +25.6% |
| FY2023 | Dec 31, 2023 | 97M | +49.8% |
| FY2022 | Dec 31, 2022 | 65M | +25.0% |
| FY2021 | Dec 31, 2021 | 52M | +75.7% |
| FY2020 | Dec 31, 2020 | 30M | +678.5% |
| FY2019 | Dec 31, 2019 | 4M | +4.6% |
| FY2018 | Dec 31, 2018 | 4M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 144M | +6.2% |
| Q1 FY2026 | Mar 31, 2026 | 140M | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | 136M | +0.9% |
| Q3 FY2025 | Sep 30, 2025 | 136M | +10.1% |
| Q2 FY2025 | Jun 30, 2025 | 136M | +16.0% |
| Q1 FY2025 | Mar 31, 2025 | 136M | +21.5% |
| Q4 FY2024 | Dec 31, 2024 | 135M | +31.9% |
| Q3 FY2024 | Sep 30, 2024 | 124M | +21.7% |
| Q2 FY2024 | Jun 30, 2024 | 117M | +19.6% |
| Q1 FY2024 | Mar 31, 2024 | 112M | +29.6% |
| Q4 FY2023 | Dec 31, 2023 | 103M | +29.8% |
| Q3 FY2023 | Sep 30, 2023 | 102M | +64.0% |
| Q2 FY2023 | Jun 30, 2023 | 98M | +61.2% |
| Q1 FY2023 | Mar 31, 2023 | 86M | +49.8% |
| Q4 FY2022 | Dec 31, 2022 | 79M | +49.6% |
| Q3 FY2022 | Sep 30, 2022 | 62M | +18.8% |
| Q2 FY2022 | Jun 30, 2022 | 61M | +18.1% |
| Q1 FY2022 | Mar 31, 2022 | 58M | +12.5% |
| Q4 FY2021 | Dec 31, 2021 | 53M | +3.6% |
| Q3 FY2021 | Sep 30, 2021 | 52M | +2.5% |
| Q2 FY2021 | Jun 30, 2021 | 52M | +336.4% |
| Q1 FY2021 | Mar 31, 2021 | 51M | +1163.6% |
| Q4 FY2020 | Dec 31, 2020 | 51M | +1185.3% |
| Q3 FY2020 | Sep 30, 2020 | 51M | +1219.5% |
| Q2 FY2020 | Jun 30, 2020 | 12M | +220.5% |
| Q1 FY2020 | Mar 31, 2020 | 4M | +10.3% |
| Q4 FY2019 | Dec 31, 2019 | 4M | – |
| Q3 FY2019 | Sep 30, 2019 | 4M | – |
| Q2 FY2019 | Jun 30, 2019 | 4M | – |
| Q1 FY2019 | Mar 31, 2019 | 4M | – |
See a number that looks wrong?